Prevents nausea and vomiting. ANDA 76960, held by Hikma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 76960 (Ondansetron Hydrochloride), held by Hikma, was first approved by FDA on Dec 26, 2006, with 9 approved supplements and 0 published complete response letters.
Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2. initial and repeat courses of moderately emetogenic cancer chemotherapy. radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 4MG BASE/5ML · solution;oral | Ondansetron Hydrochloride | Rx |
| Sep 15, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 23, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 23, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 14, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 14, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 2, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 17, 2012 | Supplement 3Labeling | Approved | None posted |
| Oct 13, 2011 | Supplement 2Labeling | Approved | None posted |
| Nov 30, 2010 | Supplement 1Labeling | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters